Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
19 April 2024
|
20:03 | Template:KDRG 2 changes history +60 [Kosar Doraghi (2×)] | |||
|
20:03 (cur | prev) +129 Kosar Doraghi talk contribs | ||||
|
19:53 (cur | prev) −69 Kosar Doraghi talk contribs |
|
m 19:50 | Non-degenerate nucleotides per response element 3 changes history −4,464 [Marshallsumter (3×)] | |||
m |
|
19:50 (cur | prev) −5,407 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
07:50 (cur | prev) +779 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
01:58 (cur | prev) +164 Marshallsumter talk contribs (→Tabulation of counts) |
N 16:30 | Sparsentan diffhist +8,644 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...") |
|
16:24 | (Upload log) [Kosar Doraghi (4×)] | |||
|
16:24 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg | ||||
|
16:14 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg | ||||
|
16:11 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg | ||||
|
16:05 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg |
16:17 | Somatic symptom disorder diffhist +485 Badgettrg talk contribs (→Treatment) |
18 April 2024
|
m 22:49 | Non-degenerate nucleotides per response element 4 changes history +2,760 [Marshallsumter (4×)] | |||
m |
|
22:49 (cur | prev) +564 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
20:37 (cur | prev) +1,206 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
08:39 (cur | prev) +727 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
04:35 (cur | prev) +263 Marshallsumter talk contribs (→Tabulation of counts) |
|
m 18:29 | Xenobiotic response element gene transcriptions 2 changes history +93 [Marshallsumter (2×)] | |||
m |
|
18:29 (cur | prev) +29 Marshallsumter talk contribs (→QRDRE analysis and results) | |||
m |
|
18:27 (cur | prev) +64 Marshallsumter talk contribs (→QRDRE analysis and results) |
12:48 | User:Edzelco diffhist +96 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
|
12:45 | Momelotinib 2 changes history +34,070 [Edzelco (2×)] | |||
|
12:45 (cur | prev) −220 Edzelco talk contribs | ||||
|
12:44 (cur | prev) +34,290 Edzelco talk contribs |
12:12 | Motixafortide diffhist +26,053 Edzelco talk contribs |
11:49 | Pozelimab-bbfg diffhist +2,390 Edzelco talk contribs |
11:42 | Palovarotene diffhist +39,181 Edzelco talk contribs |
11:16 | Elranatamab-bcmm diffhist +32,847 Edzelco talk contribs |
06:18 | Endocarditis overview diffhist +2,588 Kosar Doraghi talk contribs |
17 April 2024
|
N 20:47 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 3 changes history +364 [Hafiza Amna Qadeer (3×)] | |||
|
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit | ||||
|
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit | ||||
N |
|
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page) |
m 18:11 | Non-degenerate nucleotides per response element diffhist +438 Marshallsumter talk contribs (→Tabulation of counts) |
N 08:08 | Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:08 | Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:08 | Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:07 | Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:07 | Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:06 | Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:05 | Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:05 | Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:03 | Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
|
08:02 | User:Edzelco 5 changes history +99 [Edzelco (5×)] | |||
|
08:02 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:53 (cur | prev) +26 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:44 (cur | prev) 0 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:44 (cur | prev) +36 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:43 (cur | prev) +19 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
N 08:02 | Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...") |
|
N 07:53 | Taurolidine, heparin 2 changes history +9,993 [Edzelco (2×)] | |||
|
07:53 (cur | prev) 0 Edzelco talk contribs | ||||
N |
|
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...") |
N 07:43 | Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...") |